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Aims: To review all laboratory-conﬁrmed cases of nocardiosis at a tertiary referral hospital over an extended
period (20002018; 216months) with regard to microbiological and epidemiological characteristics, risk
factors, clinical management, morbidity and mortality.
Methods: The medical records and microbiological data of all laboratory-conﬁrmed cases of nocardiosis, iden-
tiﬁed by culture (with reference laboratory conﬁrmation) or identiﬁed in a reference laboratory only, were
included and analysed retrospectively.
Results: 18 cases of nocardiosis were identiﬁed; 72% (n = 13) were male; all were UK resident. Median age at
presentation was 56 years (range 683 years). Most had underlying pathology or risk factors including can-
cer in 39% (n = 7) and immunosuppression in 33% (n = 6). Alcohol and acid fast bacilli (AAFB) microscopy per-
formed in 8/18 cases was negative. Routine 48-hour bacterial culture of 18 isolates was positive in 15; 3
culture-negative specimens were subsequently conﬁrmed positive in a reference laboratory. Four patterns of
clinical presentation were observed: cerebral 39% (n = 7), disseminated 28% (n = 5), pulmonary 17% (n = 3),
and isolated cutaneous/articular (both n = 1). In addition one case of bacteraemia was noted. Nocardia farcin-
ica accounted for half (n = 9) of all nocardia species identiﬁed. 55% (n = 10) required surgical intervention.
One co-trimoxazole resistant isolate was identiﬁed. Morbidity and mortality were high: 78% (n = 14) required
critical care. More than half of patients (55%; n = 10) died from refractory infection, including all of those with
disseminated disease (n = 5).
Conclusions: Nocardia spp should never be regarded as a contaminant or commensal organism in clinical
specimens. Correlation of clinical and radiology ﬁndings plus risk factors are imperative for nocardiosis to be
considered in the differential diagnosis in order to guide appropriate laboratory processing of specimens.
Although rare, recognition of nocardiosis is important because of its high mortality. Routine 48-hour bacterial
culture does not always identify Nocardia spp and isolates should also be sent to a reference laboratory.
© 2019 The Authors. Published by Elsevier Ltd on behalf of British Infection Association. This is an open
access article under the CC BY-NC-ND license. (http://creativecommons.org/licenses/by-nc-nd/4.0/)Keywords:
Nocardiosis
London
PCR
Immunosuppressionr).
d on behalf of British Infection Association. This is an open access article under the CC BY-NC-ND license.Introduction
Nocardia spp are globally-distributed, ubiquitous, saprophytic bacte-
ria found in fresh and salt water, dust, soil, decomposing environmental
vegetation and organic matter (including animal faecal matter); human
acquisition is usually exogenous.18,22 The genus was named after Dr.
Edmond Nocard, a 19th-century French veterinarian and microbiologist
(18501903), who described the identiﬁcation of a pathogenic aerobic
actinomycete in cattle with bovine farcy in 1888.14 The genus Nocardia
currently contains more than 80 species, of which approximately 30
have been associated with human disease to date, but this number is
increasing due to improved access to molecular diagnostics.6 Health-
care-associated transmission or acquisition of Nocardia spp has beendocumented, but is relatively rare, and therefore Nocardia spp are not
considered to be readily communicable.8,10
Nocardiosis is an indolent subacute process and only one third of
all nocardiosis clinical cases occur in immunocompetent patients.3,4
The presence of Nocardia spp should never be regarded as a contami-
nant or commensal organism in clinical specimens.24 Primary cutane-
ous and soft tissue nocardiosis usually occurs in immunocompetent
hosts with the development of cellulitis or a superﬁcial abscess,
which can occasionally be complicated by lymphatic spread, known
as lymphocutaneous nocardiosis or sporotrichoid nocardiosis.13 Pul-
monary nocardiosis is the most common clinical presentation as
inhalation is the primary route of bacterial exposure.16 Cerebral
nocardiosis commonly accompanies pulmonary disease, but isolated
cerebral disease may also occur.5 Conditions associated with an
increased risk of nocardiosis include solid-organ transplantation,
haematological malignancies, HIV, long-term steroid treatment,
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(COPD) and other medications that suppress cell-mediated immu-
nity.7,21,25 Bacteraemia with Nocardia spp is rarely reported, even in
the context of disseminated disease.11
This 18-year retrospective single-centre review of nocardiosis is
one of the largest published to date in the United Kingdom (UK). It
details the breadth of presentations of nocardiosis to a tertiary refer-
ral hospital and provides insights into risk factors, antimicrobial
treatments, morbidity, mortality and diagnostic challenges for this
rarely-encountered pathogen.
Materials and methods
Study design
This was a retrospective case-notes review of all laboratory-
conﬁrmed cases of nocardiosis, either identiﬁed on culture, and con-
ﬁrmed in a reference laboratory, or identiﬁed in a reference laboratory
only, during the 216month study period (January 1st 2000-December
31st 2018). Samples with discordant results, such as a local positive cul-
ture but a different result from a reference laboratory, were excluded.
Study setting
St George's Hospital (SGH) is a 1300-bed tertiary referral univer-
sity teaching hospital in south west London, UK, which provides neo-
natal, paediatric, obstetric and adult medical/surgical care. It is a
specialist centre for trauma, stroke, neurosurgery, cardiothoracic sur-
gery, haematology/oncology and renal transplantation.
Study data acquisition
A line list was generated from the microbiology laboratory results sys-
tem (APEX) of all in-house culture-positive Nocardia spp clinical speci-
mens during the study period. For each culture-positive Nocardia spp
result, a manual check of reference laboratory results was performed to
ensure that results correlated. A search was also conducted of reference
laboratory reports from culture-negative specimens fromwhich a positive
result for Nocardia spp was subsequently conﬁrmed. For each clinical case
identiﬁed, a manual review of medical records (either paper or electronic)
was performed and data was extracted regarding demographics, age at
diagnosis of nocardiosis, presenting symptoms of nocardiosis, background
medical/surgical history, immunosuppressive risk factors, management of
nocardiosis (outpatient, inpatient, critical care admissions), antimicrobial
therapy employed/duration of treatment, complications of treatment, out-
patient follow-up and outcome. A review of all radiographic results was
conductedwhere relevant.
Results
Cases meeting inclusion and exclusion criteria
In total, 19 Nocardia spp positive specimens were identiﬁed. After
exclusion of one culture-positive case in which Streptomyces spp
were conﬁrmed on partial sequencing of 16S rDNA, 18 cases were
included in this study.
Epidemiology and case demographics
Of the 18 cases, 13 (72%) were male. The median age was 56 years
(range 683 years). 22% of cases (n = 4) were transferred from
another centre, although a prior diagnosis of nocardiosis had not
been made in any of these cases. All cases were permanent UK resi-
dents although two (cases 2 and 12) had travelled to India in the
weeks prior to presentation.Past medical and surgical history/immunosuppressive risk factors
Of patients included in the study, almost all— 83% (n = 15) had back-
ground medical or surgical diagnoses (Table 1). A third (cases 2, 6, 7, 8,
14, and 15) were on immunosuppressive medications as maintenance
therapy for a variety of respiratory, vasculitic, haematological and rheu-
matological conditions or as post-transplant immunosuppression
including long-term prednisolone (cases 6, 7, 14, and 15), azathioprine
(case 2), mycophenolate mofetil (cases 6, 7, and 8), hydroxychloroquine
(cases 8 and 15), methotrexate (case 8), and cyclosporine (case 7). Over
a third — 39% (n = 7) had a history of cancer although none were on
active treatment with either chemotherapy or radiotherapy at the time
of nocardiosis diagnosis. None were taking co-trimoxazole prophylaxis
at diagnosis. Only 17% (cases 5, 15, and 18) of patients were tested for
human immunodeﬁciency virus (HIV) as part of their initial investiga-
tion for nocardiosis; all were negative.
Microbiological characteristics
Diagnostic methodologies used for detection of Nocardia are out-
lined in Table 2. Eight samples assessed by alcohol and acid fast bacilli
(AAFB) microscopy were negative. Various clinical specimens were
either culture positive, or identiﬁed predominantly from partial
sequencing of 16S rDNA, including cerebral pus, cerebrospinal ﬂuid
(CSF), blood cultures, sputum, tissue samples (empyema, sternal tis-
sue), lymph nodes and wound swabs. 83% (n = 15) of cases had
in-house samples that were culture positive for Nocardia spp. Three
culture-negative samples were positive for Nocardia spp at an exter-
nal reference laboratory. 28% (n = 5) of samples were not sent to a ref-
erence laboratory. N. farcinica accounted for 50% (n = 9) of all nocardia
specimens identiﬁed. 28% (n = 5) of specimens were identiﬁed as
Nocardia spp without further identiﬁcation. Other Nocardia species
identiﬁed included N. asteroides (n = 1), N. transvalensis (n = 1), N.
ignorata (n = 1), and N. puris (n = 1). Matrix-assisted laser desorption/
ionisation time-of-ﬂight mass spectrometry (MALDI TOF-MS)
(Bruker) was introduced in our centre in 2012. Results from MALDI
TOF-MS identiﬁcation were available for four isolates; case 14 (N. far-
cinica score 2.1), case 15 (N. farcinica score 1.9), case 17 (N. farcinica
score 2.0), case 18 (N. farcinica score 1.8).
Antimicrobial susceptibility testing results
Antimicrobial susceptibility testing results are shown in Table 3.
Only one co-trimoxazole resistant isolate was detected from 12
tested; case 5. Seven isolates out of eight tested were moxiﬂoxacin
susceptibility. Of ten clinical specimens tested, all were susceptible to
imipenem and meropenem and carbapenems were used in the anti-
microbial treatment of six patients. Nine isolates were tested for line-
zolid susceptibility; all were susceptible.
Clinical presentation of nocardiosis and clinical management
Details of clinical management and outcome are summarised in
Table 4. Four clinical patterns of nocardiosis were identiﬁed during
this study.
Cerebral nocardiosis
Isolated cerebral nocardiosis accounted for the highest proportion
of cases in this study- seven cases (39%; cases 3, 5, 7, 8, 13, 15, and
18). The median age at presentation was 61 years (range
3583 years; males n = 5). N. farcinica accounted for the largest num-
ber of cerebral isolates (n = 4). Three cases (7, 17, and 18) had multi-
ple brain abscesses noted on initial computerised tomography (CT)
brain scan; the remainder of cases presented with solitary brain
abscess. All seven cases were treated with surgical drainage plus anti-
microbials; 57% (n = 4) patients died.
Table 1
Epidemiological and microbiological characteristics.
Case Age
(years)
Sex
F =
Female
M =
Male
Clinical presentation Radiographic
ﬁndings
Background medical conditions Clinical form
of nocardiosis
Nocardia spp
identiﬁed
1 42 F Dry cough Symmetrical
mediastinal
lymphadenopathy
None Pulmonary Nocardia
asteroides
2 59 M Reduced Glasgow coma scale, left
arm weakness, multiple skin lesions
Empyema
Frontal lobe ring
enhancing lesion
Pulmonary ﬁbrosis, granulomatous polymyositis Disseminated
(cerebral,
cutaneous,
pulmonary)
Nocardia
farcinica
3 35 F Seizures Multiple cerebral
abscesses
Common variable immunodeﬁciency syndrome,
non-Hodgkins lymphoma, bronchiectasis, idiopathic
thrombocytopenic purpura (ITP), splenectomy
Cerebral Nocardia
farcinica
4 36 F Headaches, night sweats, weight loss None Previous pulmonary tuberculosis, Grave's Disease Pulmonary Nocardia spp
(unspeciated)
5 57 M Recent dental abscess drainage,
headache
Temporal lobe ring
enhancing lesion
None Cerebral Nocardia spp
(unspeciated)
6 75 M Weight loss, cough New cavitatory
lung lesion
Mycobacterium avium intracellulare (MAI)— on
treatment at presentation (rifampicin, ethambutol,
clarithromycin), previous aspergilloma, childhood
polio, ITP, splenectomy
Pulmonary Nocardia
transvalensis
7 73 M Headache, pyrexia Multiple cerebral
abscesses
Prostate cancer, renal transplant, type 2 diabetes
mellitus (T2DM)
Cerebral Nocardia
farcinica
8 70 F Headache, nausea, photophobia,
dysarthria, vertigo, 3-stone weight
loss in previous 12months
Cerebellar ring
enhancing lesion
Bronchiectasis, rheumatoid arthritis Cerebral Nocardia
ignorata
9 6 F Community-acquired pneumonia Bronchopneumonia Asthma Bacteraemia Nocardia spp
(unspeciated)
10 47 M Surgical site infection (aortic valve
replacement)
Sternal
osteomyelitis
Inherited connective tissue disorder Sternal
osteomyelitis
Nocardia farcinica
11 61 M Community-acquired pneumonia,
upper gastrointestinal bleed
Lobar pneumonia Meningioma Disseminated
(pulmonary,
bacteraemia)
Nocardia puris
12 79 M Recent blunt injury sole of left foot—
stepped on a nail, multiple skin
abscesses with enlarged lymph
nodes left leg
Pulmonary nodules
Enlarged cervical
lymph nodes
Chronic kidney disease, emphysema, giant cell arteri-
tis, chronic inﬂammatory demyelinating polyneurop-
athy, T2DM, recurrent non-typhoidal Salmonella spp
bacteraemia
Disseminated
(cutaneous,
pulmonary,
epicardial)
Nocardia
farcinica
13 83 M Dysphasia, dysgraphia, right-sided
facial weakness
Temporal lobe ring
enhancing lesion
Bladder cancer Cerebral Nocardia spp
(unspeciated)
14 57 M Headache, dysphagia Frontal lobe ring
enhancing lesion
Metastatic lung cancer Disseminated
(bacteraemia,
cerebral)
Nocardia
farcinica
15 61 M Nausea, vomiting, tremor, abnormal
gait, headache
Cerebellar ring
enhancing lesion
Antisynthetase syndrome (Anti Jo-1), tongue & oro-
pharyngeal cancer, interstitial lung disease
Cerebral Nocardia
farcinica
16 59 M Nasal bridge abscess post-outdoor
trauma
No imaging None Cutaneous Nocardia spp
(unspeciated)
17 67 M Skin abscesses Multiple cerebral
abscesses
Prostate cancer Disseminated
(cutaneous,
cerebral)
Nocardia
farcinica
18 49 M Headache, vertigo, slurred speech,
ataxia
Cerebellar ring
enhancing lesions
Obesity, gastric bypass surgery, renal stones Cerebral Nocardia
farcinica
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There were ﬁve cases of disseminated nocardiosis (28%): case 2 —
cerebral, cutaneous, pulmonary; case 11 — pulmonary, bacteraemia;
case 12 — cutaneous, pulmonary, epicardial; case 14 — cerebral, bac-
teraemia; case 17 — cutaneous, cerebral. The median age at presenta-
tion was 65 years (range 5779 years); males n = 5. Case 14 did not
receive antimicrobial treatment as care was palliative. As outlined in
Table 1, all cases were immunosuppressed at presentation. All cases
of disseminated nocardiosis died.
Pulmonary nocardiosis
Three cases of pulmonary nocardiosis were identiﬁed (17%; cases
1, 4, and 6). Case 1 was referred with suspected sarcoidosis and case
4 with suspected recurrence of pulmonary tuberculosis; both diagno-
ses were subsequently ruled out. Case 1 and case 4 did not receive
antimicrobial therapy for nocardiosis and both were discharged. Nei-
ther case presented again to this hospital. Case 6 had a signiﬁcantrespiratory past medical history (aspergilloma, Mycobacterium avium
intracellulare infection) and received prolonged inpatient and outpa-
tient treatment for a cavitatory lung lesion from which samples cul-
tured positive for N. transvalensis.
Cutaneous and articular nocardiosis
Only one case of isolated cutaneous nocardiosis (case 16) was
identiﬁed, a nasal bridge abscess, secondary to mild trauma sustained
outdoors. He received empiric therapy for skin/soft tissue infection.
There was no documentation in his medical records of the positive
culture result for Nocardia spp and no record of a change in antimi-
crobial therapy on the basis of laboratory results but the patient
never presented to this hospital again. One case of radiographically
conﬁrmed sternal osteomyelitis due to N. farcinica, related to a post-
operative aortic valve replacement surgical site infection was identi-
ﬁed (case 10). The case required prolonged antimicrobial therapy
plus multiple sternal wound debridements in theatre.
Table 2
Diagnostic methodologies for Nocardia diagnosis and results.
Case Year Local microscopy/culture results Reference laboratory
result
Reference laboratory
method
Clinical sample(s) AAFBa
microscopy
AAFB
cultureb
Routine bacterial 48 h
culture
1 2000 Mediastinal lymph node Negative Positive Negative Positive Unknown
2 2001 Cerebral pus
Skin swabs also culture positive at referring
hospital
Negative Negative Positive Positive Unknown
3 2001 Cerebral pus NDd ND Positive Positive Unknown
4 2014 Sputum Negative Positive Negative Positive Unknown
5 2005 Cerebral pus ND ND Positive Positive Unknown
6 2005 Fine needle aspirate of lung abscess Negative Positive Positive Not sent NAc
7 2006 Cerebral pus ND ND Positive Not sent NA
Cerebrospinal ﬂuid ND ND Positive Not sent NA
8 2006 Cerebral pus ND ND Positive Positive Partial sequencing of 16S
rDNA
9 2006 Blood culture ND ND Positive Positive Partial sequencing of 16S
rDNA
10 2007 Tissue sternum ND ND Positive Positive Partial sequencing of 16S
rDNA
11 2009 Sputum ND ND Positive Positive Partial sequencing of 16S
rDNA
Blood culture ND ND Positive Positive Partial sequencing of 16S
rDNA
Wound swab chest ND ND Positive Positive Partial sequencing of 16S
rDNA
12 2011 Neck lymph node Negative Negative Positive Positive Partial sequencing of 16S
rDNA
13 2015 Cerebral pus Negative Negative Negative Positive Partial sequencing of 16S
rDNA
14 2015 Blood culture ND ND Positive Not sent NA
15 2017 Cerebral pus Negative Negative Positive Positive Partial sequencing of 16S
rDNA
16 2017 Wound swab nose ND ND Positive Not sent NA
17 2018 Wound swab skin ND ND Positive Positive Partial sequencing of 16S
rDNA
18 2018 Cerebral pus Negative Positive Positive Positive Partial sequencing of 16S
rDNA
a Alcohol and acid fast bacilli.
b AAFB culture positive for Nocardia spp only.
c Not applicable.
d Not done.
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Isolated bacteraemia with no clinical or microbiological evidence
of dissemination was only observed in one case, the only paediatric
case in this series, a 6-year old asthmatic presenting with commu-
nity-acquired pneumonia requiring respiratory support. A blood cul-
ture taken on admission ﬂagged positive with Nocardia spp after the
child had been discharged. No respiratory specimen was received for
processing in the laboratory and she was treated successfully with
azithromycin. No nocardia speciﬁc treatment was given. The child
did represent again to this hospital, between 2006 and 2018, but
never with clinical signs or symptoms related to sequelae of
untreated nocardiosis.
Complications arising from antimicrobial treatment of nocardiosis
Case 15 developed a reversible pancytopenia related to use of
intravenous co-trimoxazole necessitating a change of antimicrobial
treatment. Case 18 developed a severe transaminitis secondary to co-
trimoxazole, which improved on drug cessation. Case 17 experienced
unilateral hearing loss related to amikacin administration, which par-
tially improved, and also encephalopathy secondary to imipenem,
which resolved on cessation of imipenem. Case 18 developed anae-
mia secondary to linezolid and reduced from twice-daily to once-
daily dosing on day 45.
Nocardiosis morbidity and mortality
Case 2 developed a bilateral ﬂaccid paralysis of his lower limbs
following the drainage of his cerebral abscess. Case 6 developedClostridium difﬁcile colitis. Case 8 became colonised with methicillin-
resistant Staphylococcus aureus (MRSA), developed an MRSA pneu-
monia and died following a respiratory arrest. Case 10 also became
colonised with (MRSA) and his sternal wound subsequently became
infected with MRSA necessitating treatment. Case 11 developed bilat-
eral pneumothoraces and died shortly after. Case 12 was the only
patient who experienced a recurrence of local disease in his left foot
while on suppressive therapy in 2013. Most patients (78%; n = 14),
required admission to critical care at some stage. Overall, 55% (n = 10)
died secondary to refractory infection, including all 5 disseminated
cases, 4/7 cerebral cases, and 1/3 pulmonary cases.Discussion
Nocardiosis is a rare disease with a high mortality that can have a
myriad of clinical presentations as described in this 18-year retro-
spective study — the largest nocardiosis case series to date published
in the UK. From reviewing the medical notes of all 18 cases, it is strik-
ing that nocardiosis was not an expected result in any case, empha-
sising the need for microbiologists and infectious diseases clinicians
to keep nocardiosis in the differential diagnosis if the clinical presen-
tation arouses suspicion and to consider empiric cover. This study
also identiﬁed four cases where there was no acknowledgement of
the Nocardia spp result in the medical notes, which represents an
area for clinical improvement. As far as we can tell, none of these
cases presented again with progressive disease.
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period9 in the south of France, showed some similarities to our study;
their median age was similar (55.4 years; range 794 years), and the
male-preponderance was replicated (70.6%). Malignancy predominated
as a risk factor for immunosuppression and N. farcinicawas the most fre-
quently identiﬁed Nocardia spp.9 However, only 38% of French patients
underwent surgery in comparison to 53% in our study. Mortality was
also lower at 11.7%, but deaths occurred in disseminated, pulmonary
and cerebral nocardiosis, as seen in London. A recently published epide-
miological study ofNocardia isolates from human samples (53.8% pulmo-
nary) from a French laboratory dedicated to Nocardia (Observatoire
Franc¸ais des Nocardioses) also showed a predominance of Nocardia far-
cinica (20.2% of 793 isolates; 20102015) with the proportion of N. far-
cinica increasing signiﬁcantly over time from 13% in 2010 to 27.6% in
2014.12 In comparison, a large study from Thailand reviewed 70 cases20
with a reported mortality of 20%.20 This study differed though from both
this and the French study in that pulmonary nocardiosis was the most
common clinical presentation and one third of cases were HIV positive
—whereas no cases reviewed in London or France were HIV positive.
There is no international consensus with regard to the optimum anti-
microbial agents or duration of treatment for nocardiosis. As shown in
Table 4 there was variation in our study with regard to duration of treat-
ment and antimicrobial agents employed. Existing recommendations are
largely based on observational studies and expert opinion; three months
for cutaneous disease, at least six months for pulmonary or disseminated
infections and at least 12months if there is central nervous system
involvement, but there is no agreement on duration of IV therapy or for
how long total treatment should be prolonged in the immunosup-
pressed.1 The antimicrobial management of nocardiosis is challenging as
antimicrobial susceptibility patterns can vary widely amongst Nocardia
spp and combination therapy is recommended. Current Australian
guidelines recommend co-trimoxazole plus at least one other agent.2
Recent studies have found that 75%89% of Nocardia spp were sensitive
to co-trimoxazole.2,17,19 In our study, only one co-trimoxazole resistant
isolate was detected from 12 available but antimicrobial data was miss-
ing for six cases, which is a limitation of our study. Combination therapy
with co-trimoxazole and a carbapenem, if susceptible, is recommended
if invasive infection is suspected as in vitro synergism has been demon-
strated.9 The French epidemiological study by Lebeaux et al.12 reviewed
antimicrobial susceptibility testing (AST) and their results were broadly
similar to ours. Linezolid, amikacin, trimethoprim-sulfamethoxazole,
minocycline and imipenem were the most frequently identiﬁed active
antibiotics with, 0% (0/734), 2.9% (21/730), 5.4% (40/734), 9.4% (69/734)
and 19.5% (143/732), respectively of isolates not susceptible. Interest-
ingly, 79.7% (118/148) of N. farcinica isolates were not susceptible to
cefotaxime which differs to our AST result where 91% (11/12 isolates)
were susceptible.20 Regardless of what antimicrobial agents are used, as
demonstrated in this study, serious complications from therapy can arise
and patients on prolonged nocardiosis treatment need diligent monitor-
ing for physical and biochemical adverse events.
The diagnosis of nocardiosis can be challenging as the bacteria is
difﬁcult to culture and grows slowly but molecular diagnostics have
made identiﬁcation quicker and more precise. Partial sequencing of
16S rDNA is the most commonly used method as the gene is highly
conserved and contains regions present in all species as well as vari-
able regions that are species speciﬁc.14,23 We recommend that all iso-
lates are sent to a reference laboratory for PCR conﬁrmation. The use
of MALDI TOF-MS to aid the identiﬁcation of Nocardia spp is not
completely robust but is evolving. A recent paper reported that the
use of the commercial database alone and in combination with an in-
house library afforded 94.5% and 95.9% of correct species-level identi-
ﬁcations, respectively; no isolate was misidentiﬁed at the genus level
with either database.15 Our experience of using MALDI TOF-MS for
identiﬁcation demonstrated a variance in scores, some below 2.0, but
reassuringly all results correlated with conﬁrmatory reference labo-
ratory results.
Table 4
Clinical management and outcome.
Case Clinical form
of nocardiosis
Nocardia
spp
identiﬁed
Nocardiosis management
Surgery Antimicrobial therapy
[duration— days]
Outcome
[days between nocardiosis
diagnosis and death]
Intravenous therapy Oral therapy
1 Pulmonary Nocardia
asteroides
N/A None None Discharged
2 Disseminated Nocardia
farcinica
Yes Co-trimoxazole [68 days], cefotaxime [68 days],
metronidazole [68 days]
None Died
[66 days]
3 Cerebral Nocardia
farcinica
Yes Co-trimoxazole [25 days], ceftriaxone [25 days],
clindamycin [25 days]
Co-trimoxazole [497 days] Died
[522 days]
4 Pulmonary Nocardia
spp
No None None Discharged
5 Cerebral Nocardia
spp
Yes Meropenem [21 days], co-trimoxazole [21 days] Moxiﬂoxacin [365 days] Discharged
6 Pulmonary Nocardia
transvalensis
No None Co-trimoxazole [356 days] Died
[356 days]
7 Cerebral Nocardia
farcinica
Yes Co-trimoxazole [58 days], metronidazole
[61 days], amoxicillin [61 days], cefotaxime
[61 days]
None Died
[58 days]
8 Cerebral Nocardia
ignorata
Yes Cefotaxime [17 days], metronidazole [17 days] Moxiﬂoxacin [2 days] Died
[16 days]
9 Bacteraemia Nocardia
spp
No None None Discharged
10 Sternal osteomyelitis Nocardia
farcinica
Yes None Co-trimoxazole [14 days],
co-amoxiclav [63 days],
ciproﬂoxacin [185 days]
Discharged
11 Disseminated Nocardia
puris
Yes Co-amoxiclav [8 days], clarithromycin [8 days],
piperacillin-tazobactam [9 days], gentamicin
[9 days]
*Treatment withdrawn
None Died
[30 days]
12 Disseminated Nocardia
farcinica
No Meropenem [228 days], co-trimoxazole
[228 days]
Co-amoxiclav [2026 days] Died
[2646 days]
13 Cerebral Nocardia
spp
Yes Meropenem [12 days while in St George's] None Discharged, interhospital
transfer — lost to follow-up
14 Disseminated Nocardia
farcinica
No None
*Palliative at diagnosis
None Died
[5 days]
15 Cerebral Nocardia
farcinica
Yes Meropenem [4 days], imipenem [68 days],
co-trimoxazole [7 days]
Moxiﬂoxacin [73 days],
co-trimoxazole [145 days]
Died
[226 days]
16 Cutaneous Nocardia
spp
No None None Discharged
17 Disseminated Nocardia
farcinica
No Imipenem [6 days], amikacin [22 days], merope-
nem [42 days], co-trimoxazole [42 days]
Moxiﬂoxacin [48 days],
co-trimoxazole [48 days]
Died
[90 days]
18 Cerebral Nocardia
farcinica
Yes Imipenem [28 days], co-trimoxazole [5 days],
meropenem [day 33 to date; on-going]
Moxiﬂoxacin [day 43 to date;
on-going], linezolid [day 58 to
date; on-going]
Discharged on outpatient
antimicrobial therapy (OPAT)
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6 C. O’Connor et al. / Clinical Infection in Practice 1 (2019) 100004In conclusion, nocardiosis is uncommon in the UK and even large
specialist centres will see cases very infrequently. Patients with nocar-
diosis usually have a predisposing risk factor for immunosuppression
but nocardiosis can also present in immunocompetent patients. Multi-
disciplinary management is essential, antimicrobial treatment is gener-
ally prolonged and mortality is high depending on the anatomical site
(s) of infection. The clinical complexity of nocardiosis cannot be over-
stated and the signiﬁcance of clinical isolates should not be overlooked.
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